CN1210517A - 用于治疗结缔组织降解相关性疾病的新的异羟肟酸衍生物 - Google Patents
用于治疗结缔组织降解相关性疾病的新的异羟肟酸衍生物 Download PDFInfo
- Publication number
- CN1210517A CN1210517A CN97192171A CN97192171A CN1210517A CN 1210517 A CN1210517 A CN 1210517A CN 97192171 A CN97192171 A CN 97192171A CN 97192171 A CN97192171 A CN 97192171A CN 1210517 A CN1210517 A CN 1210517A
- Authority
- CN
- China
- Prior art keywords
- oxo
- hydroxyl
- pyrrolidine
- methylpropyl
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 C=CCC(C(*I)N)C(O)=O Chemical compound C=CCC(C(*I)N)C(O)=O 0.000 description 4
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D231/08—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with oxygen or sulfur atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1309896P | 1996-03-08 | 1996-03-08 | |
| US60/013,098 | 1996-03-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1210517A true CN1210517A (zh) | 1999-03-10 |
Family
ID=21758301
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN97192171A Pending CN1210517A (zh) | 1996-03-08 | 1997-03-03 | 用于治疗结缔组织降解相关性疾病的新的异羟肟酸衍生物 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US5712300A (https=) |
| EP (1) | EP0898562B1 (https=) |
| JP (1) | JP2000506163A (https=) |
| KR (1) | KR19990087597A (https=) |
| CN (1) | CN1210517A (https=) |
| AT (1) | ATE231490T1 (https=) |
| AU (1) | AU707180B2 (https=) |
| BR (1) | BR9707947A (https=) |
| DE (1) | DE69718634T2 (https=) |
| DK (1) | DK0898562T3 (https=) |
| ES (1) | ES2191823T3 (https=) |
| ID (1) | ID16144A (https=) |
| MY (1) | MY117762A (https=) |
| NO (1) | NO312956B1 (https=) |
| NZ (1) | NZ330922A (https=) |
| PE (1) | PE55698A1 (https=) |
| PL (1) | PL328693A1 (https=) |
| PT (1) | PT898562E (https=) |
| RU (1) | RU2168497C2 (https=) |
| TW (1) | TW448172B (https=) |
| UA (1) | UA61906C2 (https=) |
| WO (1) | WO1997032846A1 (https=) |
| ZA (1) | ZA971902B (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100336809C (zh) * | 2002-03-13 | 2007-09-12 | 史密丝克莱恩比彻姆公司 | 肽脱甲酰酶抑制剂 |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5932579A (en) | 1996-06-18 | 1999-08-03 | Affymax Technologies N.V. | Collagenase-1 and stromelysin-1 inhibitors, pharmaceutical compositions comprising same and methods of their use |
| PT1021424E (pt) * | 1996-06-21 | 2003-06-30 | Upjohn Co | Amidas de tiadiazolo como inibidores da metaloproteinase de matriz |
| KR20000048639A (ko) * | 1996-09-27 | 2000-07-25 | 로렌스 티. 마이젠헬더 | 매트릭스 메탈로프로테이나제 억제제인 베타-술포닐 히드록삼산 |
| GB9702088D0 (en) | 1997-01-31 | 1997-03-19 | Pharmacia & Upjohn Spa | Matrix metalloproteinase inhibitors |
| WO1998039326A1 (en) * | 1997-03-04 | 1998-09-11 | Monsanto Company | Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds |
| US6566373B2 (en) | 1997-05-06 | 2003-05-20 | Smithkline Beecham Corporation | Protease inhibitors |
| AR013079A1 (es) * | 1997-05-06 | 2000-12-13 | Smithkline Beecham Corp | Derivados sustituidos de tetrahidrofurano-3-onas, de tetrahidropirano-3- onas y tetrahidrotiofen-3-onas, un procedimiento para su preparacion unacomposicion farmaceutica de un medicamento util como inhibidores de proteasas e intermediarios |
| US5883131A (en) * | 1997-07-09 | 1999-03-16 | Pfizer Inc. | Cyclic sulfone derivatives |
| CA2298617A1 (en) | 1997-07-31 | 1999-02-11 | Yetunde Olabisi Taiwo | Acyclic metalloprotease inhibitors |
| DE19741235A1 (de) * | 1997-09-18 | 1999-03-25 | Hoechst Marion Roussel De Gmbh | Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| US6403632B1 (en) | 2000-03-01 | 2002-06-11 | Bristol Myers Squibb Pharma Co | Lactam metalloprotease inhibitors |
| ZA988967B (en) * | 1997-10-03 | 2000-04-03 | Du Pont Pharm Co | Lactam metalloprotease inhibitors. |
| EP1024134A4 (en) * | 1997-10-09 | 2003-05-14 | Ono Pharmaceutical Co | DERIVATIVES OF AMINOBUTANIC ACID |
| EP1004578B1 (en) * | 1998-11-05 | 2004-02-25 | Pfizer Products Inc. | 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives |
| GB9825988D0 (en) * | 1998-11-27 | 1999-01-20 | Pfizer Ltd | Indole derivatives |
| US20040122011A1 (en) * | 1998-12-23 | 2004-06-24 | Pharmacia Corporation | Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy |
| BR0008716A (pt) | 1999-03-03 | 2002-09-24 | Procter & Gamble | Inibidores de metaloprotease contendo alquenil ou alquinil |
| MXPA01008857A (es) | 1999-03-03 | 2002-07-02 | Procter & Gamble | Inhibidores de metaloproteasa dihetero sustituidos. |
| EP1165546A2 (en) * | 1999-04-02 | 2002-01-02 | Du Pont Pharmaceuticals Company | Novel lactam inhibitors of matrix metalloproteinases, tnf-alpha, and aggrecanase |
| US6797820B2 (en) | 1999-12-17 | 2004-09-28 | Vicuron Pharmaceuticals Inc. | Succinate compounds, compositions and methods of use and preparation |
| WO2002028829A2 (en) * | 2000-09-25 | 2002-04-11 | Questcor Pharmaceuticals, Inc. | Peptide deformylase inhibitors |
| CA2434205A1 (en) | 2001-01-11 | 2002-07-18 | Dupont Pharmaceuticals Company | 1,1-disubstituted cyclic inhibitors of matrix metalloprotease and tnf-.alpha. |
| AU2002246983A1 (en) | 2001-01-11 | 2002-07-24 | Bristol-Myers Squibb Pharma Company | 1,2-disubstituted cyclic inhibitors of matrix metallorproteases and tnf-alpha |
| WO2002070654A2 (en) * | 2001-03-01 | 2002-09-12 | Smithkline Beecham Corporation | Peptide deformylase inhibitors |
| EP1406893B1 (en) * | 2001-06-15 | 2007-04-18 | Vicuron Pharmaceuticals, Inc. | Pyrrolidine bicyclic compounds |
| AR036053A1 (es) | 2001-06-15 | 2004-08-04 | Versicor Inc | Compuestos de n-formil-hidroxilamina, un proceso para su preparacion y composiciones farmaceuticas |
| PE20030701A1 (es) | 2001-12-20 | 2003-08-21 | Schering Corp | Compuestos para el tratamiento de trastornos inflamatorios |
| US7622117B2 (en) * | 2002-04-17 | 2009-11-24 | Dynamis Therapeutics, Inc. | 3-deoxyglucosone and skin |
| KR100701811B1 (ko) * | 2002-05-29 | 2007-04-02 | 머크 앤드 캄파니 인코포레이티드 | 탄저병의 치료 및 치사 인자의 억제에 유용한 화합물 |
| US20050176686A1 (en) * | 2002-07-23 | 2005-08-11 | 4Sc Ag | Novel compounds as histone deacetylase inhibitors |
| US7846963B2 (en) * | 2003-05-17 | 2010-12-07 | Korea Research Institute Of Bioscience And Biotechnology | 2-oxo-heterocyclic compounds and the pharmaceutical compositions comprising the same |
| US7122560B2 (en) | 2003-06-18 | 2006-10-17 | Bristol-Myers Squibb Company | Lactam derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme |
| EP1663201A4 (en) * | 2003-07-15 | 2009-10-28 | Korea Res Inst Of Bioscience | USE OF NOVEL 2-OXO-HETEROCYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME |
| ES2398237T3 (es) * | 2003-07-23 | 2013-03-14 | Novartis Ag | Uso de calcitonina en osteoartritis |
| AU2005250351A1 (en) * | 2004-05-11 | 2005-12-15 | Merck & Co., Inc. | Process for making n-sulfonated-amino acid derivatives |
| US20100003276A1 (en) * | 2004-12-07 | 2010-01-07 | Hermes Jeffery D | Methods for treating anthrax and inhibiting lethal factor |
| DE102004060229A1 (de) * | 2004-12-15 | 2006-06-29 | Sanofi-Aventis Deutschland Gmbh | Neue zyklische Harnstoffe als Inhibitoren von Metallproteasen |
| KR20090028846A (ko) * | 2005-01-28 | 2009-03-19 | 아이알엠 엘엘씨 | 페닐-치환 피롤리돈 |
| GB0811643D0 (en) | 2008-06-25 | 2008-07-30 | Cancer Rec Tech Ltd | New therapeutic agents |
| FR2947268B1 (fr) * | 2009-06-30 | 2011-08-26 | Galderma Res & Dev | Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique |
| WO2012031298A2 (en) | 2010-09-03 | 2012-03-08 | Duke University | Ethynylbenzene derivatives |
| US20140081017A1 (en) * | 2012-09-14 | 2014-03-20 | Methylgene Inc. | Histone Deacetylase Inhibitors for Enhancing Activity of Antifungal Agents |
| US10647664B2 (en) | 2013-08-16 | 2020-05-12 | Duke University | Substituted hydroxamic acid compounds |
| WO2015024021A2 (en) | 2013-08-16 | 2015-02-19 | Duke University | Antibacterial compounds |
| WO2015024016A2 (en) * | 2013-08-16 | 2015-02-19 | Duke University | 2-piperidinyl substituted n,3-dihydroxybutanamides |
| GB201517217D0 (en) | 2015-09-29 | 2015-11-11 | Astex Therapeutics Ltd And Cancer Res Technology Ltd | Pharmaceutical compounds |
| GB201517216D0 (en) | 2015-09-29 | 2015-11-11 | Cancer Res Technology Ltd And Astex Therapeutics Ltd | Pharmaceutical compounds |
| GB201704966D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| GB201704965D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1360583A (en) * | 1918-02-18 | 1920-11-30 | Great Lakes Dredge And Dock Co | Car-dumper |
| EP0042100A1 (de) * | 1980-06-13 | 1981-12-23 | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft | Pyrazolopyridazin-Derivate, Zwischenprodukte und Verfahren zu deren Herstellung, sowie diese enthaltende Arzneimittel |
| DE3420193A1 (de) * | 1984-05-30 | 1985-12-05 | Boehringer Ingelheim KG, 6507 Ingelheim | Neue substituierte pyrrolidinone, verfahren zu ihrer herstellung und arzneimittel |
| AU4267293A (en) * | 1992-05-01 | 1993-11-29 | British Biotech Pharmaceuticals Limited | Use of MMP inhibitors |
| US5318964A (en) * | 1992-06-11 | 1994-06-07 | Hoffmann-La Roche Inc. | Hydroxamic derivatives and pharmaceutical compositions |
| AU681396B2 (en) * | 1993-03-31 | 1997-08-28 | G.D. Searle & Co. | 1-amidinophenyl-pyrrolidones piperidinones azetinones as platelet aggregation inhibitors |
| EP0712390B1 (en) * | 1993-08-02 | 1998-12-09 | Celltech Therapeutics Limited | Succinamide derivatives, processes for their preparation and their use as gelatinase and collagenase inhibitors |
| GB9320660D0 (en) * | 1993-10-07 | 1993-11-24 | British Bio Technology | Inhibition of cytokine production |
| US5403952A (en) * | 1993-10-08 | 1995-04-04 | Merck & Co., Inc. | Substituted cyclic derivatives as novel antidegenerative agents |
-
1997
- 1997-02-21 TW TW086102076A patent/TW448172B/zh not_active IP Right Cessation
- 1997-03-03 EP EP97908674A patent/EP0898562B1/en not_active Expired - Lifetime
- 1997-03-03 PL PL97328693A patent/PL328693A1/xx unknown
- 1997-03-03 DE DE69718634T patent/DE69718634T2/de not_active Expired - Fee Related
- 1997-03-03 WO PCT/US1997/002568 patent/WO1997032846A1/en not_active Ceased
- 1997-03-03 ES ES97908674T patent/ES2191823T3/es not_active Expired - Lifetime
- 1997-03-03 RU RU98118372/04A patent/RU2168497C2/ru not_active IP Right Cessation
- 1997-03-03 NZ NZ330922A patent/NZ330922A/xx unknown
- 1997-03-03 JP JP9531784A patent/JP2000506163A/ja not_active Withdrawn
- 1997-03-03 AU AU20525/97A patent/AU707180B2/en not_active Ceased
- 1997-03-03 BR BR9707947A patent/BR9707947A/pt active Search and Examination
- 1997-03-03 AT AT97908674T patent/ATE231490T1/de not_active IP Right Cessation
- 1997-03-03 KR KR1019980707039A patent/KR19990087597A/ko not_active Abandoned
- 1997-03-03 PT PT97908674T patent/PT898562E/pt unknown
- 1997-03-03 UA UA98105283A patent/UA61906C2/uk unknown
- 1997-03-03 CN CN97192171A patent/CN1210517A/zh active Pending
- 1997-03-03 DK DK97908674T patent/DK0898562T3/da active
- 1997-03-04 PE PE1997000155A patent/PE55698A1/es not_active Application Discontinuation
- 1997-03-04 US US08/811,821 patent/US5712300A/en not_active Expired - Fee Related
- 1997-03-05 ZA ZA971902A patent/ZA971902B/xx unknown
- 1997-03-06 ID IDP970713A patent/ID16144A/id unknown
- 1997-03-07 MY MYPI97000965A patent/MY117762A/en unknown
-
1998
- 1998-09-07 NO NO19984112A patent/NO312956B1/no unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100336809C (zh) * | 2002-03-13 | 2007-09-12 | 史密丝克莱恩比彻姆公司 | 肽脱甲酰酶抑制剂 |
Also Published As
| Publication number | Publication date |
|---|---|
| ATE231490T1 (de) | 2003-02-15 |
| NO984112D0 (no) | 1998-09-07 |
| EP0898562B1 (en) | 2003-01-22 |
| TW448172B (en) | 2001-08-01 |
| ID16144A (id) | 1997-09-04 |
| PE55698A1 (es) | 1998-09-16 |
| ES2191823T3 (es) | 2003-09-16 |
| KR19990087597A (ko) | 1999-12-27 |
| UA61906C2 (en) | 2003-12-15 |
| AU2052597A (en) | 1997-09-22 |
| US5712300A (en) | 1998-01-27 |
| NO984112L (no) | 1998-11-06 |
| PL328693A1 (en) | 1999-02-15 |
| EP0898562A1 (en) | 1999-03-03 |
| NO312956B1 (no) | 2002-07-22 |
| DE69718634D1 (de) | 2003-02-27 |
| DK0898562T3 (da) | 2003-05-12 |
| JP2000506163A (ja) | 2000-05-23 |
| NZ330922A (en) | 2000-01-28 |
| ZA971902B (en) | 1998-09-07 |
| RU2168497C2 (ru) | 2001-06-10 |
| WO1997032846A1 (en) | 1997-09-12 |
| AU707180B2 (en) | 1999-07-01 |
| MY117762A (en) | 2004-08-30 |
| DE69718634T2 (de) | 2003-10-30 |
| BR9707947A (pt) | 1999-07-27 |
| PT898562E (pt) | 2003-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1210517A (zh) | 用于治疗结缔组织降解相关性疾病的新的异羟肟酸衍生物 | |
| CN1049654C (zh) | 哌嗪衍生物及含其的药物组合物和用途 | |
| CN1257891C (zh) | 含氮五员环化合物 | |
| CN1024547C (zh) | 一类环胺化合物的制备方法 | |
| CN1049434C (zh) | 芳族脒衍生物及其可药用盐的制备方法 | |
| CN1077886C (zh) | 用作一氧化一氮合酶抑制剂的脒基衍生物 | |
| CN1045595C (zh) | 合成3－氨基哌啶衍生物的中间体的制备方法 | |
| CN1273128C (zh) | 取代的n－[(氨基亚氨基甲基或氨基甲基)苯基]丙基酰胺 | |
| CN1805929A (zh) | 磷酸二酯酶4抑制剂 | |
| CN1281433A (zh) | 作为基质金属蛋白酶(mmp)抑制剂的异羟肟酸衍生物 | |
| CN87107371A (zh) | 螺-取代的戊二酰胺利尿剂 | |
| CN1298404A (zh) | 磷脂酶a2的抑制剂 | |
| CN1064683A (zh) | 新的β-氨基-α羟基羧酸及其用途 | |
| CN1279680A (zh) | 具有法尼基转移酶抑制活性的咪唑衍生物及其制备方法 | |
| CN1681804A (zh) | 乙内酰脲衍生物以及用作tace抑制剂的用途 | |
| CN86100964A (zh) | 哌啶化合物的制备方法 | |
| CN1173170A (zh) | 基质金属蛋白酶抑制剂 | |
| CN1079396C (zh) | 用作选择性凝血酶抑制剂的芳族脒衍生物 | |
| CN1134153A (zh) | 基质金属蛋白酶抑制剂 | |
| CN1740169A (zh) | 用作类胰蛋白酶抑制剂的芳基甲胺衍生物 | |
| CN1129934A (zh) | 苯并吖庚因衍生物及其药物组合物和中间体 | |
| CN1950357A (zh) | 用作tafia抑制剂的咪唑衍生物 | |
| CN1078469A (zh) | 取代吲哚、氨杂吲哚和四氢-1H-吡咯并[2，3-c]吡啶-7-酮衍生物 | |
| CN1606443A (zh) | 作为催产素拮抗剂的取代的二酮哌嗪类 | |
| CN1151148C (zh) | 具有吡咯结构的法尼转移酶抑制剂及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1018447 Country of ref document: HK |